A Synthetic Peptide Blocking the Apolipoprotein E/β-Amyloid Binding Mitigates β-Amyloid Toxicity and Fibril Formation in Vitro and Reduces β-Amyloid Plaques in Transgenic Mice

Sadowski, Marcin; Pankiewicz, Joanna; Scholtzova, Henrieta; Ripellino, James A.; Li, Yongsheng; Schmidt, Stephen D.; Mathews, Paul M.; Fryer, John D.; Holtzman, David M.; Sigurdsson, Einar M.; Wisniewski, Thomas

doi:10.1016/s0002-9440(10)63355-x

Cited by 154Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

A Synthetic Peptide Blocking the Apolipoprotein E/β-Amyloid Binding Mitigates β-Amyloid Toxicity and Fibril Formation in Vitro and Reduces β-Amyloid Plaques in Transgenic Mice

Open access

Sadowski, Marcin, Pankiewicz, Joanna, Scholtzova, Henrieta, Ripellino, James A., Li, Yongsheng, Schmidt, Stephen D., Mathews, Paul M., Fryer, John D. +3 more·2004·The American Journal of Pathology

DOI 10.1016/s0002-9440(10)63355-xPMC PMC1618605

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer's disease (AD) is associated with accumulation of beta-amyloid (Abeta). A major genetic risk factor for sporadic AD is inheritance of the apolipoprotein (apo) E4 allele. ApoE can act as a pathological chaperone of Abeta, promoting its conformational transformation from soluble Abeta into toxic aggregates. We determined if blocking the apoE/Abeta interaction reduces Abeta load in transgenic (Tg) AD mice. The binding site of apoE on Abeta corresponds to residues 12 to 28. To block binding, we synthesized a peptide containing these residues, but substituted valine at position 18 to proline (Abeta12-28P). This changed the peptide's properties, making it non-fibrillogenic and non-toxic. Abeta12-28P competitively blocks binding of full-length Abeta to apoE (IC50 = 36.7 nmol). Furthermore, Abeta12-28P reduces Abeta fibrillogenesis in the presence of apoE, and Abeta/apoE toxicity in cell culture. Abeta12-28P is blood-brain barrier-permeable and in AD Tg mice inhibits Abeta deposition. Tg mice treated with Abeta12-28P for 1 month had a 63.3% reduction in Abeta load in the cortex (P = 0.0043) and a 59.5% (P = 0.0087) reduction in the hippocampus comparing to age-matched control Tg mice. Antibodies against Abeta were not detected in sera of treated mice; therefore the observed therapeutic effect of Abeta12-28P cannot be attributed to an antibody clearance response. Our experiments demonstrate that compounds blocking the interaction between Abeta and its pathological chaperones may be beneficial for treatment of beta-amyloid deposition in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0002-9440(10)63355-x

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Aβ12-28P is a nontoxic, synthetic peptide modified for increased BBB permeability and extended serum half-life.
“The ApoE/Ab binding was blocked with Ab12-28P, which is a nontoxic, synthetic peptide modified for increased blood-brain-barrier (BBB) permeability and extended serum half-life.16”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [16]
The Synthetic Peptides and Proteins section describes Aβ12-28P as synthetic and modified to extend its half-life; the introductory passage says a sequence substitution made it nontoxic. The Pharmacokinetic and Blood-Brain Barrier Permeability Studies section shows that it crosses the BBB, but does not say the modifications increased BBB permeability; its measured distribution did not differ significantly from the comparator. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured
The toxicity of Aβ at micromolar concentration was a potential stumbling block.
“As previously reported, the toxicity of Aβ at micromolar concentration was a potential stumbling block in a recent study.18”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [18]
Experimental — accuracy not yet measured
ApoE directly interacts with Aβ, binding to its amino-acid residues 12-28, to exert its promoting effect on Aβ aggregation and brain deposition.
“To exert its promoting effect on Aβ aggregation and brain deposition, apoE directly interacts with Aβ, binding to its amino-acid residues 12–28 [11,12].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [12]
Aβ12-28P is a nontoxic synthetic peptide modified for in vivo application, and its blood-brain barrier permeability was previously evaluated and reported.
“Ab12-28P is a nontoxic synthetic peptide that was modified for in vivo application, and its BBB permeability was previously evaluated and reported.16”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [16]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · see citing works
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works
Computed circular dichroism spectra for the evaluation of protein conformation
Greenfield, N. J., & Fasman, G. D. (1969) · Biochemistry · doi:10.1021/bi00838a031 · Cited by 3,697 · see citing works
The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Application to the radioimmunoassay
Bolton, A. E., & Hunter, W. M. (1973) · Biochemical Journal · doi:10.1042/bj1330529 · Cited by 3,269 · see citing works
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works
Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994 · see citing works
Some new, simple and efficient stereological methods and their use in pathological research and diagnosis.
GUNDERSEN, H. J. G., BENDTSEN, T. F., KORBO, L., MARCUSSEN, N., MØLLER, A., NIELSEN, K., NYENGAARD, J. R., PAKKENBERG, B., SØRENSEN, F. B., VESTERBY, A., et al. (1988) · APMIS · doi:10.1111/j.1699-0463.1988.tb05320.x · Cited by 2,929 · see citing works
A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR
Petkova, A. T., Ishii, Y., Balbach, J. J., Antzutkin, O. N., Leapman, R. D., Delaglio, F., & Tycko, R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262663499 · Cited by 1,847 · see citing works
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525 · see citing works
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,488 · see citing works
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,453 · see citing works
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426 · see citing works
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · see citing works
Self-citation
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · see citing works
Long-term dendritic spine stability in the adult cortex
Grutzendler, J., Kasthuri, N., & Gan, W.-B. (2002) · Nature · doi:10.1038/nature01276 · Cited by 1,198 · see citing works
Unbiased stereological estimation of the number of neurons in the human hippocampus
West, M. J., & Gundersen, H. J. G. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902960102 · Cited by 1,153 · cited 1× · see citing works
“If this condition is met, adding more test areas does not enhance the accuracy of stereological measurements.(59) Such a sampling scheme designed in a fully random and unbiased manner helps to counterbalance the natural tendency of A to be deposited in a non-homogenous manner in AD Tg mice.”
Background
The Protein Protocols Handbook
Walker, J. M. (2009) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-59745-198-7 · Cited by 1,137 · see citing works
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · see citing works
A Self-Consistent Method for the Analysis of Protein Secondary Structure from Circular Dichroism
Sreerama, N., & Woody, R. W. (1993) · Analytical Biochemistry · doi:10.1006/abio.1993.1079 · Cited by 1,056 · see citing works
Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment
Morton, D. B., & Griffiths, P. (1985) · Veterinary Record · doi:10.1136/vr.116.16.431 · Cited by 1,039 · see citing works
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · see citing works
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · see citing works
Self-citation
Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871 · see citing works
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830 · see citing works
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · see citing works
Variable selection method improves the prediction of protein secondary structure from circular dichroism spectra
Manavalan, P., & Johnson, W. C. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90135-7 · Cited by 715 · see citing works
Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease
Barrow, C. J., Yasuda, A., Kenny, P. T. M., & Zagorski, M. G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90106-t · Cited by 636 · see citing works
A γ‐secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497 · cited 1× · see citing works
“Compared to vaccination(87) or -secretase inhibitors,(88) blocking of pathological chaperones is not associated with the risk of an autoimmune reaction or affecting multiple signaling pathways including Notch-1 and wnt.(86) Animals treated with A 12–28P did not produce a humoral response related to the peptide’s small…”
Background
Apolipoprotein E is essential for amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., Fishman, C. E., DeLong, C. A., Piccardo, P., Petegnief, V., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15233 · Cited by 486 · see citing works
The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192203399 · Cited by 447 · see citing works
Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
(1994) · PubMed Central · Cited by 441 · see citing works
Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: A practical guide
Perczel, A., Park, K., & Fasman, G. D. (1992) · Analytical Biochemistry · doi:10.1016/0003-2697(92)90046-a · Cited by 436 · see citing works
Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits
Holcomb, L. A., Gordon, M. N., Jantzen, P., Hsiao, K., Duff, K., & Morgan, D. (1999) · Behavior Genetics · doi:10.1023/a:1021691918517 · Cited by 353 · see citing works
Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease
Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · see citing works
Self-citation
Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.
Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh‐Navikas, S., Hancock, W. W., & Selkoe, D. J. (2000) · PubMed · Cited by 310 · see citing works
The Origins of Alzheimer Disease
Selkoe, D. J. (2000) · JAMA · doi:10.1001/jama.283.12.1615 · Cited by 285 · see citing works
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging
Wadghiri, Y. Z., Sigurdsson, E. M., Sadowski, M. J., Elliott, J. I., Li, Y., Scholtzova, H., Tang, C. Y., Aguinaldo, G., Pappolla, M. A., Duff, K., et al. (2003) · Magnetic Resonance in Medicine · doi:10.1002/mrm.10529 · Cited by 273 · see citing works
Self-citation
Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides
TOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480359 · Cited by 272 · see citing works
Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E
Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., & Frangione, B. (1995) · Biochemical Journal · doi:10.1042/bj3060599 · Cited by 267 · see citing works
The Protein protocols handbook
McPhie, P. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00682-6 · Cited by 265 · see citing works
Apolipoprotein E: Binding to Soluble Alzheimer′s β-Amyloid
Wısnıewskı, T., Golabek, A. A., Matsubara, E., Ghiso, J. A., & Frangione, B. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1423 · Cited by 265 · see citing works
Nasal administration of amyloid-? peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh‐Navikas, S., Hancock, W. W., & Selkoe, D. J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200010)48:4 · Cited by 261 · see citing works
Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice
Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., & Wısnıewskı, T. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61715-4 · Cited by 258 · see citing works
Self-citation
Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (−/−), and Human apoE Transgenic Mice
Fagan, A. M., Holtzman, D. M., Munson, G., Mathur, T., Schneider, D., Chang, L. K., Getz, G. S., Reardon, C. A., Lukens, J., Shah, J. A., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30001 · Cited by 222 · see citing works
Self-citation
Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide
Permanne, B., Adessi, C., Saborı́o, G. P., Fraga, S., Frossard, M., Dorpe, J. V., Dewachter, I., Banks, W. A., LEUVEN, F. V., & Soto, C. A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0841fje · Cited by 218 · see citing works
Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins.
Sun, Y., Wu, S., Bu, G., Onifade, M. K., Patel, S. N., LaDu, M. J., Fagan, A. M., & Holtzman, D. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03261.1998 · Cited by 213 · see citing works
Self-citation
Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed byIn VivoMultiphoton Microscopy
Christie, R. H., Bacskai, B. J., Zipfel, W. R., Williams, R. M., Kajdasz, S. T., Webb, W. W., & Hyman, B. T. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00858.2001 · Cited by 197 · see citing works
Characterization of Apolipoprotein J-Alzheimer's Aβ Interaction
Matsubara, E., Frangione, B., & Ghiso, J. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7563 · Cited by 195 · see citing works
Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.
Maggio, J. E., Stimson, E. R., Ghilardi, J. R., Allen, C. J., Dahl, C. E., Whitcomb, D. C., Vigna, S. R., Vinters, H. V., Labenski, M. E., & Mantyh, P. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5462 · Cited by 194 · see citing works
Signaling Events in Amyloid β-Peptide-induced Neuronal Death and Insulin-like Growth Factor I Protection
Wei, W., Wang, X., & Kusiak, J. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111704200 · Cited by 190 · see citing works
Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain
Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanović, N., Gandy, S., Lannfelt, L., Terenius, L. Y., & Nordstedt, C. (1995) · Neuron · doi:10.1016/0896-6273(95)90079-9 · Cited by 189 · see citing works
Apolipoprotein J and Alzheimer's amyloid β solubility
Matsubara, E., Soto, C. A., Governale, S., Frangione, B., & Ghiso, J. A. (1996) · Biochemical Journal · doi:10.1042/bj3160671 · Cited by 187 · see citing works
γ-Secretase inhibitors repress thymocyte development
Hadland, B., Manley, N. R., Su, D., Longmore, G. D., Moore, C. L., Wolfe, M. S., Schroeter, E. H., & Kopan, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131202798 · Cited by 186 · see citing works
Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes
McGowan, E. M., Sanders, S., Iwatsubo, T., Takeuchi, A., Saido, T. C., Zehr, C., Yu, X., Uljon, S., Wang, R., Mann, D. M. A., et al. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0243 · Cited by 183 · see citing works
Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice
DeMattos, R. B., Brendza, R. P., Heuser, J. E., Kierson, M., Cirrito, J. R., Fryer, J., Sullivan, P. M., Fagan, A. M., Han, X., & Holtzman, D. M. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00049-3 · Cited by 180 · see citing works
Self-citation
Blood-Brain Barrier Transport of Circulating Alzheimer′s Amyloid β
Zloković, B. V., Ghiso, J. A., Mačkić, J. B., McComb, J. G., Weiss, M. H., & Frangione, B. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2582 · Cited by 175 · see citing works
Is Alzheimer's disease an apolipoprotein E amyloidosis?
Wisniewski, T., Lalowski, M., Golabek, A., Frangione, B., & Vogel, T. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90701-7 · Cited by 155 · see citing works
Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic xray diffraction pattern
Gorevic, P. D., Castaño, E. M., Sarma, R., & Frangione, B. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)91008-4 · Cited by 153 · see citing works
Presenilin-dependent γ-secretase activity modulates thymocyte development
Doerfler, P., Shearman, M. S., & Perlmutter, R. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161102498 · Cited by 152 · see citing works
The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice
Lanz, T. A., Himes, C. S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., & Merchant, K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048280 · Cited by 147 · see citing works
Cerebrovascular transport of Alzheimer's amyloidβ and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier
Zloković, B. V. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00310-4 · Cited by 138 · see citing works
The Interaction between Apolipoprotein E and Alzheimer's Amyloid β-Peptide Is Dependent on β-Peptide Conformation
Golabek, A. A., Soto, C. A., Vogel, T., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10602 · Cited by 137 · see citing works
The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid
Lalowski, M. M., Golabek, A. A., Lemere, C. A., Selkoe, D. J., Wı́sniewski, H. M., Beavis, R. C., Frangione, B., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33623 · Cited by 134 · see citing works
Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer′s Amyloid β
Zloković, B. V., Martel, C. L., Mačkić, J. B., Matsubara, E., Wısnıewskı, T., McComb, J. G., Frangione, B., & Ghiso, J. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2825 · Cited by 133 · see citing works
Extending CD spectra of proteins to 168 nm improves the analysis for secondary structures
Toumadje, A., Alcorn, S. W., & Johnson, W. C. (1992) · Analytical Biochemistry · doi:10.1016/0003-2697(92)90473-k · Cited by 125 · see citing works
Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides
Ma, J., Brewer, H. B., & Potter, H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00112-1 · Cited by 108 · see citing works
Amyloid β binding proteins in vitro and in normal human cerebrospinal fluid
Golabek, A., Marques, M. A., Lalowski, M., & Wisniewski, T. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11565-7 · Cited by 99 · see citing works
Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain
Wengenack, T. M., Whelan, S. L., Curran, G. L., Duff, K., & Poduslo, J. F. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00388-2 · Cited by 97 · see citing works
Targeting Alzheimer amyloid plaques in vivo
Wengenack, T. M., Curran, G. L., & Poduslo, J. F. (2000) · Nature Biotechnology · doi:10.1038/78482 · Cited by 88 · see citing works
Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice
Ji, Y., Permanne, B., Sigurdsson, E. M., Holtzman, D. M., & Wısnıewskı, T. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3105 · Cited by 83 · see citing works
Self-citation
Receptor-Mediated Transport of Human Amyloid β-Protein 1–40 and 1–42 at the Blood–Brain Barrier
Poduslo, J. F., Curran, G. L., Sanyal, B., & Selkoe, D. J. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0238 · Cited by 83 · see citing works
In Vivo Reversal of Amyloid-β Lesions in Rat Brain
Sigurdsson, E. M., Permanne, B., Soto, C. A., Wısnıewskı, T., & Frangione, B. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.1.11 · Cited by 83 · see citing works
Self-citation
Diffuse, Lake-like Amyloid-β Deposits in the Parvopyramidal Layer of the Presubiculum in Alzheimer Disease
Wisniewski, H. M., Sadowski, M., Jakubowska-Sadowswka, K., Tarnawski, M., & Wegiel, J. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199807000-00004 · Cited by 71 · see citing works
Self-citation
Alzheimer β Amyloid Deposition Enhanced by ApoE ɛ4 Gene precedes Neurofibrillary pathology in the Frontal Association Cortex of Nondemented Senior Subjects
Yamaguchi, H., Sugihara, S., Ogawa, A., Oshima, N., & Ihara, Y. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.7.731 · Cited by 56 · see citing works
Pattern of neuronal loss in the rat hippocampus following experimental cardiac arrest-induced ischemia
Sadowski, M., Wı́sniewski, H. M., Jakubowska-Sadowska, K., Tarnawski, M. J., Łazarewicz, J. W., & Mossakowski, M. J. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00159-8 · Cited by 52 · see citing works
Self-citation
Alzheimer disease's double-edged vaccine
Greenberg, S. M., Bacskai, B. J., & Hyman, B. T. (2003) · Nature Medicine · doi:10.1038/nm847 · Cited by 51 · see citing works
Induced expression of neuronal membrane attack complex and cell death by Alzheimer's β-amyloid peptide
Shen, Y., Sullivan, T., Lee, C., Meri, S., Shiosaki, K., & Lin, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00346-1 · Cited by 46 · see citing works
Presenilin-Dependent Gamma-Secretase Activity Modulates Neurite Outgrowth
Figueroa, D. J., Morris, J. A., Ma, L., Kandpal, G., Chen, E., Li, Y., & Austin, C. P. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0447 · Cited by 37 · see citing works
Self-citation
Interaction between human amphipathic apolipoproteins and amyloid β‐peptide: surface plasmon resonance studies
Shuvaev, V. V., & Siest, G. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00206-2 · Cited by 36 · see citing works
Neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Gearing, M., & Nash, F. (1997) · Neurology · doi:10.1212/wnl.49.3_suppl_3.s14 · Cited by 34 · see citing works
Alzheimerʼs β-amyloid peptide is conformationally modified by apolipoprotein E in vitro
Soto, C. A., Golabek, A. A., Wısnıewskı, T., & Castaño, E. M. (1996) · Neuroreport · doi:10.1097/00001756-199602290-00010 · Cited by 32 · see citing works
Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate
Vaidyanathan, G., Affleck, D. J., & Zalutsky, M. R. (1993) · Bioconjugate Chemistry · doi:10.1021/bc00019a011 · Cited by 23 · see citing works
Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease
Tomiyama, T., Corder, E. H., & Mori, H. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050428 · Cited by 21 · see citing works
Preparation of Avidin Conjugates
Haugland, R. P., & Bhalgat, M. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-579-4_1 · Cited by 13 · see citing works

Flagged first, then by citations

2 of the 87 references couldn’t be matched to a known paper.

Research works printed but not linked: 13

Soto C, Golabek AA, Wisniewski T, Castan ˜o EM: Alzheimer's soluble ␤-amyloid is conformationally modified by apolipoproteins in vitro. Neuroreport 1996, 7:721-725
Perczel A, Park K, Fasman GD: Analysis of circular dichroism spec- trum of proteins using the convex constraint algorithim. Anal Biochem 1992, 203:83-93
Toumadje A, Alcorn SW, Johnson C: Extending CD spectra of pro- teins to 168nm improves the analysis for secondary structures. Anal Biochem 1992, 200:321-331
Bolton AE, Hunter WM: Labeling of proteins to high-specific radioac- tivities by conjugation to A I-125-containing acylating agent: applica- tion to radioimmunoassay. Biochem J 1973, 133:529 -538
Lalowski M, Golabek AA, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B, Wisniewski T: The "non-amyloidogenic" p3 fragment (A␤17-42) is a major constituent of Down syndrome cere- bellar preamyloid. J Biol Chem 1996, 271:33623-33631
Shargel L, Yu CEA: Applied Biopharmaceutics and Pharmakokinet- ics. New York, McGraw-Hill, 1999
Stokes A: Humane endpoints in animal experiments for laboratory animals used in toxicity testing. Proceedings of the 3rd World Con- gress on Alternatives and Animal Use in Life Sciences. Bologna, Italy, 1999
Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, Grundke-Iqbal I, Currie J, Wisniewski HM: Production and characterization of mono- clonal antibodies reactive to synthetic cerebrovascular amyloid pep- tide. Neurosci Res Commun 1988, 2:121-130
Sadowski M, Wen PH, Elder GA, Robakis NK, Wisniewski T: Effect of the presenilin 1 P117L FAD linked mutation on hippocampal morphol- ogy transgenic mice. J Neuropathol Exp Neurol 2001, 60:543
Jimenez-Huete A, Alfonso P, Soto C, Albar JP, Rabano A, Ghiso J, Frangione B: Antibodies directed to the carboxyl terminus of amyloid ␤-peptide recognize sequence epitopes and distinct immunoreactive deposits in Alzheimer's disease brain. Alzheimers Rep 1998, 1:41-47
Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM: Apoli- poprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999, 96:15233-15238
Figueroa DJ, Morris JA, Ma L, Kandpal G, Chen E, Li YM, Austin CP: Presenilin-dependent ␥-secretase activity modulates neurite out- growth. Neurobiol Dis 2002, 9:49 -60
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-␤ attenuates Alzheimer disease-like pa- thology in the PDAPP mice. Nature 1999, 400:173-177

Sorted by citations

Alzheimer’s disease
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · see citing works
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608 · see citing works
100 Years and Counting: Prospects for Defeating Alzheimer's Disease
Roberson, E. D., & Mucke, L. (2006) · Science · doi:10.1126/science.1132813 · Cited by 550 · see citing works
Interferon-γ and Tumor Necrosis Factor-α Regulate Amyloid-β Plaque Deposition and β-Secretase Expression in Swedish Mutant APP Transgenic Mice
Yamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., & Ikezu, T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060378 · Cited by 367 · see citing works
Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer’s Disease and Amyloid Neuroprotection
Buckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 312 · see citing works
Potent D-peptide inhibitors of HIV-1 entry
Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P., & Kay, M. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708109104 · Cited by 250 · see citing works
The Development of Amyloid β Protein Deposits in the Aged Brain
Thal, D. R., Capetillo-Zarate, E., Del Tredici, K., & Braak, H. (2006) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2006.6.re1 · Cited by 234 · see citing works
Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease
Peng, S., Garzon, D. J., Marchese, M., Klein, W. L., Ginsberg, S. D., Francis, B. M., Mount, H. T. J., Mufson, E. J., Salehi, A., & Fahnestock, M. L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4736-08.2009 · Cited by 216 · see citing works
APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis
Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212 · see citing works
Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis
Kim, J., Jiang, H., Park, S., Eltorai, A. E. M., Stewart, F. R., Yoon, H., Basak, J. M., Finn, M. B., & Holtzman, D. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3773-11.2011 · Cited by 199 · see citing works
“A interaction could be another attractive therapeutic approach to prevent apoE-mediated A aggregation (Sadowski et al., 2004).”
BackgroundSelf-citation
Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels
Lee, C. Y. D., Tse, W., Smith, J. D., & Landreth, G. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295451 · Cited by 178 · see citing works
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 166 · see citing works
Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease
Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167 · see citing works
Self-citation
Levels of Soluble Apolipoprotein E/Amyloid-β (Aβ) Complex Are Reduced and Oligomeric Aβ Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*
Tai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., Poon, W. W., Cornwell, L. B., Miller, C. A., Vinters, H. V., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442103 · Cited by 165 · see citing works
Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Estrada, L. D., & Soto, C. A. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607779318262 · Cited by 162 · see citing works
Design of a Potent d -Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance
Welch, B. D., Francis, J. N., Redman, J. S., Paul, S., Weinstock, M. T., Reeves, J. D., Lie, Y., Whitby, F. G., Eckert, D. M., Hill, C. P., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01339-10 · Cited by 159 · see citing works
The role of astrocytes in amyloid β-protein toxicity and clearance
Thal, D. R. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.04.021 · Cited by 146 · see citing works
Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms
Kim, J., Yoon, H., Basak, J., & Kim, J. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0248 · Cited by 141 · see citing works
“For example, an A 12- 28 synthetic peptide, which contains the apoE-binding site, reduced cerebral A accumulation in animal models of A amyloidosis (Kuszczyk et al., 2013; Pankiewicz et al., 2014; Sadowski et al., 2004; 2006).”
Background
Overexpression of Monocyte Chemotactic Protein-1/CCL2 in β-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse β-Amyloid Deposition
Yamamoto, M., Horiba, M., Buescher, J. L., Huang, D., Gendelman, H. E., Ransohoff, R. M., & Ikezu, T. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62364-4 · Cited by 137 · see citing works
Strategies for the Inhibition of Protein Aggregation in Human Diseases
Bartolini, M., & Andrisano, V. (2010) · ChemBioChem · doi:10.1002/cbic.200900666 · Cited by 136 · see citing works
Detection of amyloid plaques targeted by USPIO-Aβ1–42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging
Yang, J., Zaim Wadghiri, Y., Minh Hoang, D., Tsui, W., Sun, Y., Chung, E., Li, Y., Wang, A., de Leon, M., & Wisniewski, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.023 · Cited by 135 · see citing works
Self-citation
APOE-amyloid interaction: Therapeutic targets
Wısnıewskı, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 125 · see citing works
Apolipoprotein E Genotype and Age-Related Myelin Breakdown in Healthy Individuals
Bartzokis, G., Lu, P. H., Geschwind, D. H., Edwards, N. J., Mintz, J., & Cummings, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.1.63 · Cited by 128 · see citing works
Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer’s Disease
Wilhelmus, M. M. M., de Waal, R. M. W., & Verbeek, M. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0029-7 · Cited by 121 · see citing works
Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample
Lu, P. H., Lee, G. J., Raven, E. P., Tingus, K., Khoo, T., Thompson, P. M., & Bartzokis, G. (2011) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2011.595397 · Cited by 121 · see citing works
Role of Cholesterol in APP Metabolism and Its Significance in Alzheimer’s Disease Pathogenesis
Maulik, M., Westaway, D. A., Jhamandas, J. H., & Kar, S. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8337-y · Cited by 117 · see citing works
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117 · see citing works
Peptides for Therapy and Diagnosis of Alzheimer's Disease
Funke, S. A., & Willbold, D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799277752 · Cited by 118 · see citing works
Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk
Tai, L. M., Mehra, S., Shete, V., Estus, S., Rebeck, G. W., Bu, G., & LaDu, M. J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-2 · Cited by 116 · see citing works
Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging
Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114 · see citing works
Self-citation
Astrocytes as a Therapeutic Target in Alzheimer’s Disease–Comprehensive Review and Recent Developments
Rodríguez-Giraldo, M., González-Reyes, R. E., Ramírez-Guerrero, S., Bonilla-Trilleras, C. E., Guardo-Maya, S., & Nava-Mesa, M. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113630 · Cited by 118 · see citing works
Apolipoprotein E Affects Both Myelin Breakdown and Cognition: Implications for Age-Related Trajectories of Decline Into Dementia
Bartzokis, G., Lu, P. H., Geschwind, D. H., Tingus, K., Huang, D., Mendez, M. F., Edwards, N., & Mintz, J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.024 · Cited by 109 · see citing works
RAGE and amyloid beta interactions: Atomic force microscopy and molecular modeling
Chaney, M. O., Stine, W. B., Kokjohn, T. A., Kuo, Y., Esh, C. L., Rahman, A., Luehrs, D. C., Schmidt, A. M., Stern, D. M., Yan, S. D., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.03.014 · Cited by 109 · see citing works
Clearance and prevention of prion infection in cell culture by anti‐PrP antibodies
Pankiewicz, J. E., Prelli, F. C., Sy, M., Kascsak, R. J., Kascsak, R. B., Spinner, D. S., Carp, R. I., Meeker, H. C., Sadowski, M. J., & Wısnıewskı, T. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04805.x · Cited by 99 · see citing works
Self-citation
Roles of ApoE4 on the Pathogenesis in Alzheimer’s Disease and the Potential Therapeutic Approaches
Sun, Y.-Y., Wang, Z., & Huang, H. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01365-1 · Cited by 95 · see citing works
Disease-Modifying Therapies in Alzheimer???s Disease
ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 94 · see citing works
Understanding the Pathophysiology of Cerebral Amyloid Angiopathy
Gatti, L., Tinelli, F., Scelzo, E., Arioli, F., Fede, G. D., Obici, L. P., Pantoni, L., Giaccone, G., Caroppo, P., Parati, E. A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103435 · Cited by 94 · see citing works
Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages
Asuni, A. A., Boutajangout, A., Scholtzova, H., Knudsen, E., Li, Y. S., Quartermain, D., Frangione, B., Wısnıewskı, T., & Sigurdsson, E. M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05149.x · Cited by 91 · see citing works
Self-citation
Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration
Kuszczyk, M. A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A. A., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.034 · Cited by 89 · see citing works
Self-citation
Mirror image phage display—a method to generate d -peptideligands for use in diagnostic or therapeutical applications
Funke, S. A., & Willbold, D. (2009) · Molecular BioSystems · doi:10.1039/b904138a · Cited by 86 · see citing works
Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: Protection by diosgenin and l-deprenyl
Turchan-Cholewo, J. T., Liu, Y., Gartner, S., Reid, R., Jie, C., Peng, X., Chen, K. C., Chauhan, A., Haughey, N. J., Cutler, R. G., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.005 · Cited by 81 · see citing works
Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade
Potter, H., & Wısnıewskı, T. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/489428 · Cited by 80 · see citing works
Cerebral Small Vessel Disease-Induced Apolipoprotein E Leakage Is Associated With Alzheimer Disease and the Accumulation of Amyloid β-Protein in Perivascular Astrocytes
Utter, S., Tamboli, I. Y., Walter, J., Upadhaya, A. R., Birkenmeier, G., Pietrzik, C. U., Ghebremedhin, E., & Thal, D. R. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181836a71 · Cited by 80 · see citing works
Disrupted hippocampal growth hormone secretagogue receptor 1α interaction with dopamine receptor D1 plays a role in Alzheimer′s disease
Tian, J., Guo, L., Sui, S., Driskill, C., Phensy, A., Wang, Q., Gauba, E., Zigman, J. M., Swerdlow, R. H., Kroener, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6278 · Cited by 72 · see citing works
Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72 · see citing works
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice
Sigurdsson, E. M., Wadghiri, Y. Z., Mosconi, L., Blind, J. A., Knudsen, E., Asuni, A. A., Scholtzova, H., Tsui, W. H., Li, Y., Sadowski, M. J., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.018 · Cited by 66 · see citing works
Self-citation
The Polyphenol Piceid Destabilizes Preformed Amyloid Fibrils and Oligomers In Vitro: Hypothesis on Possible Molecular Mechanisms
Rivière, C., Delaunay, J.-C., Immel, F., Cullin, C., & Monti, J. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9883-6 · Cited by 61 · see citing works
Blocking the apolipoprotein E/Amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60 · see citing works
Self-citation
Occurrence and co-localization of amyloid β-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice
Thal, D. R., Larionov, S., Abramowski, D., Wiederhold, K., Dooren, T. V., Yamaguchi, H., Haass, C., LEUVEN, F. V., Staufenbiel, M., & Capetillo‐Zarate, E. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.029 · Cited by 59 · see citing works
Inhibitor Discovery Targeting the Intermediate Structure of β-Amyloid Peptide on the Conformational Transition Pathway: Implications in the Aggregation Mechanism of β-Amyloid Peptide
Liu, D., Xu, Y., Yu, F., Liu, H., Shen, X., Chen, K., Ma, J., & Jiang, H. (2006) · Biochemistry · doi:10.1021/bi060955f · Cited by 58 · see citing works
Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57 · see citing works
Self-citation
Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer’s Disease Related Pathology and Cognitive Decline
Liu, S., Park, S.-A., Allington, G., Prelli, F. C., Sun, Y., Martá-Ariza, M., Scholtzova, H., Biswas, G. K., Brown, B., Verghese, P. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08604-8 · Cited by 57 · see citing works
Self-citation
Cerebral Amyloid Angiopathy, Subcortical White Matter Disease and Dementia: Literature Review and Study in OPTIMA
Esiri, M. M., Chance, S. A., Joachim, C. L., Warden, D. R., Smallwood, A., Sloan, C., Christie, S., Wilcock, G. K., & Smith, A. D. (2014) · Brain Pathology · doi:10.1111/bpa.12221 · Cited by 55 · see citing works
Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration
Nielsen, A. L., Rajabi, N., Kudo, N., Lundø, K., Moreno–Yruela, C., Bæk, M., Fontenas, M., Lucidi, A., Madsen, A. S., Yoshida, M., et al. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00036a · Cited by 54 · see citing works
Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4
Bilousova, T. V., Melnik, M., Miyoshi, E., Gonzalez, B. L., Poon, W. W., Vinters, H. V., Miller, C. A., Corrada, M. M., Kawas, C. H., Hatami, A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.010 · Cited by 54 · see citing works
Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease
Wısnıewskı, T., & Frangione, B. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00102.x · Cited by 54 · see citing works
Apolipoprotein E co-localizes with newly formed amyloid β-protein (Aβ) deposits lacking immunoreactivity against N-terminal epitopes of Aβ in a genotype-dependent manner
Thal, D. R., Capetillo-Zarate, E., Schultz, C., Rüb, U., Saido, T. C., Yamaguchi, H., Haass, C., Griffin, W. S. T., Del Tredici, K., Braak, H., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1053-1 · Cited by 50 · see citing works
Diseases of protein aggregation and the hunt for potential pharmacological agents
Wang, S. S. ‐., Wu, J. W., Yamamoto, S., & Liu, H. (2007) · Biotechnology Journal · doi:10.1002/biot.200700065 · Cited by 49 · see citing works
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Aillaud, I., & Funke, S. A. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01230-7 · Cited by 49 · see citing works
Immunomodulation Targeting Abnormal Protein Conformation Reduces Pathology in a Mouse Model of Alzheimer's Disease
Goñi, F., Prelli, F. C., Ji, Y., Scholtzova, H., Yang, J., Sun, Y., Liang, F., Kascsak, R., Kascsak, R. J., Mehta, P. D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013391 · Cited by 48 · see citing works
Self-citation
Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease
Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow�, E., Horn, A. H. C., Sticht, H., Malhis, M., Will, N., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167432 · Cited by 48 · see citing works
Haptoglobin binds apolipoprotein E and influences cholesterol esterification in the cerebrospinal Fluid
Alfonso, S., Cigliano, L., Carlucci, A., Bucci, E. M., & Abrescia, P. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06121.x · Cited by 48 · see citing works
MCP-1 involvement in glial differentiation of neuroprogenitor cells through APP signaling
Vrotsos, E. G., Kolattukudy, P. E., & Sugaya, K. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.01.004 · Cited by 47 · see citing works
Alzheimer's Disease: Another Target for Heparin Therapy
Bergamaschini, L. C., Rossi, E., Vergani, C., & Simoni, M. G. D. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.100 · Cited by 46 · see citing works
Haptoglobin binds the antiatherogenic protein apolipoprotein E – impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytes
Cigliano, L., Pugliese, C. R., Spagnuolo, M. S., Palumbo, R., & Abrescia, P. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07319.x · Cited by 46 · see citing works
Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo
Sadowski, M. J., Pankiewicz, J. E., Prelli, F. C., Scholtzova, H., Spinner, D. S., Kascsak, R. B., Kascsak, R. J., & Wısnıewskı, T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.013 · Cited by 45 · see citing works
Self-citation
Peroxiredoxin 6 mediates protective function of astrocytes in Aβ proteostasis
Pankiewicz, J. E., Diaz, J. R., Martá-Ariza, M., Lizińczyk, A. M., Franco, L. A., & Sadowski, M. J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00401-8 · Cited by 45 · see citing works
Self-citation
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
de Bartolomeis, A., Vellucci, L., Austin, M., Simone, G. D., & Barone, A. (2022) · Biomolecules · doi:10.3390/biom12070909 · Cited by 40 · see citing works
Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors
Wısnıewskı, T., & Sadowski, M. J. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s5 · Cited by 42 · see citing works
Self-citation
Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Rocha, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990613 · Cited by 42 · see citing works
Binding studies of truncated variants of the Aβ peptide to the V-domain of the RAGE receptor reveal Aβ residues responsible for binding
Gospodarska, E., Kupniewska-Kozak, A., Goch, G., & Dadlez, M. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.02.011 · Cited by 41 · see citing works
Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?
Ahmed, M. M., Johnson, N. R., Boyd, T. D., Coughlan, C. M., Chial, H. J., & Potter, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.718426 · Cited by 42 · see citing works
BACE and γ-Secretase Characterization and Their Sorting as Therapeutic Targets to Reduce Amyloidogenesis
Marks, N., & Berg, M. J. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0054-1 · Cited by 38 · see citing works
Therapeutic approaches for prion and Alzheimer's diseases
Wısnıewskı, T., & Sigurdsson, E. M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05919.x · Cited by 41 · see citing works
Self-citation
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41 · see citing works
Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer’s disease
Rolyan, H., Feike, A. C., Upadhaya, A. R., Waha, A., Dooren, T. V., Haass, C., Birkenmeier, G., Pietrzik, C. U., LEUVEN, F. V., & Thal, D. R. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0572-7 · Cited by 38 · see citing works
Beyond Amyloid
Lane, R. F., Shineman, D. W., Steele, J., Lee, L. H., & Fillit, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00007-6 · Cited by 33 · see citing works
A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro
Aillaud, I., Kaniyappan, S., Chandupatla, R., Ramirez, L. M., Alkhashrom, S., Eichler, J., Horn, A. H. C., Zweckstetter, M., Mandelkow�, E., Sticht, H., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00959-z · Cited by 32 · see citing works
Novel strategies for Alzheimer's disease treatment
Spencer, B. J., Rockenstein, E. M., Crews, L. A., Marr, R. A., & Masliah, E. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.12.1853 · Cited by 31 · see citing works
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 30 · see citing works
A Survey of Peptides with Effective Therapeutic Potential in Alzheimer’s Disease Rodent Models or in Human Clinical Studies
Sun, N., Funke, S. A., & Willbold, D. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712800493942 · Cited by 30 · see citing works
Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders
Marks, N., & Berg, M. J. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.020 · Cited by 29 · see citing works
Modulation of amyloid precursor protein expression reduces β‐amyloid deposition in a mouse model
Asuni, A. A., Guridi, M., Pankiewicz, J. E., Sanchez, S., & Sadowski, M. J. (2014) · Annals of Neurology · doi:10.1002/ana.24149 · Cited by 28 · see citing works
Self-citation
Mirror image phage display – Generating stable therapeutically and diagnostically active peptides with biotechnological means
Sun, N., Funke, S. A., & Willbold, D. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.05.019 · Cited by 28 · see citing works
Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer’s Disease
Drummond, E., Goñi, F., Liu, S., Prelli, F., Scholtzova, H., & Wısnıewskı, T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179909 · Cited by 26 · see citing works
Self-citation
Aβ20–29 peptide blocking apoE/Aβ interaction reduces full-length Aβ42/40 fibril formation and cytotoxicity in vitro
Hao, J., Zhang, W., Zhang, P., Liu, R., Liu, L., Lei, G., Su, C., Miao, J., & Li, Z. (2010) · Neuropeptides · doi:10.1016/j.npep.2010.03.001 · Cited by 26 · see citing works
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28 · see citing works
Human apolipoprotein E isoforms are differentially sialylated and the sialic acid moiety in ApoE2 attenuates ApoE2-Aβ interaction and Aβ fibrillation
Moon, H.-J., Haroutunian, V., & Zhao, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105631 · Cited by 25 · see citing works
Development of a Small D-Enantiomeric Alzheimer’s Amyloid-β Binding Peptide Ligand for Future In Vivo Imaging Applications
Funke, S. A., Bartnik, D., Glück, J. M., Piorkowska, K., Wiesehan, K., Weber, U., Gulyás, B. Z., Halldin, C., Pfeifer, A., Spenger, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041457 · Cited by 24 · see citing works
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer’s disease cognition
Johnson, N. R., Wang, A. C.-J., Coughlan, C. M., Sillau, S., Lucero, E., Viltz, L., Markham, N. E., Allen, C., Dhanasekaran, A. R., Chial, H. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01020-9 · Cited by 21 · see citing works
Facile Solid-Phase Parallel Synthesis of Linear and Cyclic Peptoids for Comparative Studies of Biological Activity
Park, S., & Kwon, Y.-U. (2015) · ACS Combinatorial Science · doi:10.1021/co5001647 · Cited by 22 · see citing works
Chapter 8 The Molecular and Cellular Pathogenesis of Dementia of the Alzheimer's Type
Luque, F. A., & Jaffe, S. L. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)00408-5 · Cited by 22 · see citing works
Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20 · see citing works
Future horizons in Alzheimer's disease research
Wısnıewskı, T., & Drummond, E. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.08.001 · Cited by 20 · see citing works
Design of D-Amino Acids SARS-CoV-2 Main Protease Inhibitors Using the Cationic Peptide from Rattlesnake Venom as a Scaffold
Eberle, R. J., Gering, I., Tusche, M., Ostermann, P. N., Müller, L., Adams, O., Schaal, H., Olivier, D. S., do Amaral, M. S., Arni, R. K., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15050540 · Cited by 19 · see citing works
Human apolipoprotein E glycosylation and sialylation: from structure to function
Moon, H.-J., Luo, Y., Chugh, D., & Zhao, L. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1399965 · Cited by 18 · see citing works
Styryl-Based and Tricyclic Compounds as Potential Anti-Prion Agents
Chung, E., Prelli, F. C., Dealler, S., Lee, W. S., Chang, Y., & Wısnıewskı, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024844 · Cited by 18 · see citing works
Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer’s Disease
Leclerc, B., & Abulrob, A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/589308 · Cited by 18 · see citing works
d-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: A novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry
Laine, J., Auriola, S. O. K., Pasanen, M., & Juvonen, R. O. (2010) · Toxicology in Vitro · doi:10.1016/j.tiv.2010.11.002 · Cited by 18 · see citing works

[P‐183]: Blocking the apolipoprotein E/amyloid‐B interaction reduces amyloid‐B load in AD transgenic mice
Sadowski, M. J., Pankiewicz, J. E., Scholtzova, H., Wen, P. H., Mehta, P. D., & Wısnıewskı, T. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.06.243
Self-citation
Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease
Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167 · see citing works
Self-citation
P4–254: The apolipoprotein E/Aβ interaction as a novel therapeutic target for Alzheimer's disease
Sadowski, M. J., Pankiewicz, J. E., Scholtzova, H., Wu, H., Prelli, F. C., Mehta, P. D., Quartermain, D., & Wısnıewskı, T. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.1993
Self-citation
Aβ20–29 peptide blocking apoE/Aβ interaction reduces full-length Aβ42/40 fibril formation and cytotoxicity in vitro
Hao, J., Zhang, W., Zhang, P., Liu, R., Liu, L., Lei, G., Su, C., Miao, J., & Li, Z. (2010) · Neuropeptides · doi:10.1016/j.npep.2010.03.001 · Cited by 26 · see citing works
Blocking the apolipoprotein E/Amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60 · see citing works
Self-citation

Authors: Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., & Wisniewski, T.
Affiliations: New York University (US)
Nathan Kline Institute for Psychiatric Research (US)
Washington University in St. Louis (US)
ORCID: Scholtzova, Henrieta
Li, Yongsheng
Mathews, Paul M.
Fryer, John D.
Holtzman, David M.
Sigurdsson, Einar M.
Venue: The American Journal of Pathology
Publisher: Elsevier BV
Published: 2004-09
Volume: 165
Issue: 3
Pages: 937-948
ISSN: 0002-9440 (ISSN-L)
DOI: 10.1016/s0002-9440(10)63355-x
PMC: PMC1618605
OpenAlex: W2164642027
Cited by: 154
References: 87
Citations by year: 2026: 6 · 2025: 6 · 2024: 5 · 2023: 4 · 2022: 9 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 9 · 2013: 8 · 2012: 10
FWCI: 7.20
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: American Journal Of Pathology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (AG15408, AG20747, AG13956)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, amyloid-beta, apolipoprotein E, APOE ε4, peptide antagonists, amyloid fibril formation, amyloid plaques, transgenic mice, blood-brain barrier permeability, amyloid deposition
MeSH terms: Alzheimer Disease, Animals, Apolipoproteins E, Astrocytes, Binding Sites, Blood-Brain Barrier, Brain, Competitive Bidding, Female, Half-Life, Humans, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Neuroblastoma, Peptide Fragments, Protein Binding, Tumor Cells, Cultured, Amyloid beta-Peptides, Mice, Knockout, Mice, Presenilin-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Synthetic Peptide Blocking the Apolipoprotein E/β-Amyloid Binding Mitigates β-Amyloid Toxicity and Fibril Formation in Vitro and Reduces β-Amyloid Plaques in Transgenic Mice

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks